Michael Tees is an Oncology physician. OpenAlex indexes 93 publications with 1,118 citations (h-index 16); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1721 E 19th Ave Ste 300
Denver, CO 802181258
Telephone
720-754-4800Registry record last updated 8 Dec 2018.
Clinical trials
- Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Sponsor: SCRI Development Innovations, LLC
- A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Sponsor: SCRI Development Innovations, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202512 payments$14,468openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202515 payments
- Astellas Pharma US IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
83.2%CD38-directed Cytolytic Antibody81.1%Daratumumab100%Part B, office-administered≥20 patientsKinase inhibitor0.7%Jakafi59%Sirolimus22%Imatinib Mesylate19%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
8.4%Osmotically acting laxatives4.2%Magnesium sulfate100%Part B, office-administered≥27 patientsSerotonin-3 Receptor Antagonist2.9%Ondansetron hydrochloride92%Ondansetron Odt8%Part D + Part B≥15 patients+ 4 more classes in this area
Anti-infectives
3%Azole Antifungal0.8%Posaconazole55%Voriconazole31%Fluconazole15%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.8%Valacyclovir100%Part D≥15 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”